# Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura

> **NCT00162006** · PHASE2 · COMPLETED · sponsor: **Baxalta now part of Shire** · enrollment: 28 (actual)

## Conditions studied

- Immune Thrombocytopenic Purpura (ITP)

## Interventions

- **DRUG:** Immune Globulin Intravenous (Human), 10% Triple Virally Reduced Solution

## Key facts

- **NCT ID:** NCT00162006
- **Lead sponsor:** Baxalta now part of Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01-13
- **Primary completion:** 2003-12-03
- **Final completion:** 2003-12-03
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2021-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00162006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00162006, "Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00162006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*